Board of Directors
Executive Chairman: Carsten Lonfeldt
M.Sc. (Econ), Copenhagen Business School. Until the end of 2006, Carsten Lønfeldt was Group Director (CFO) in Coloplast A/S following a twenty-year career of management responsibilities in the company within a number of strategic key areas such as economy and finance, IT, HR, planning, corporate control and investor relations. After retiring from Coloplast, Carsten Lønfeldt has concentrated on his efforts at various board positions and is a member of the Advisory Board for OMX, the Nordic Exchange, Copenhagen, among others. Through his wide-ranging management background, his knowledge of the colorectal cancer market and broader insight into the biotech industry, Carsten Lønfeldt brings to DanDrit a particularly relevant business expertise.
Peter Buhl Jensen
Dr. Peter Buhl Jensen is Professor in Clinical Oncology at Copenhagen University, MD, DMSc and former Chief Oncologist at the Department of Oncology, Ålborg Hospital. Peter Buhl Jensen is a co-founder of the Danish cancer therapeutics company Topotarget for which he also was CEO between 2001 and 2010. Peter Buhl Jensen is currently CEO for LiPlasome Pharma ApS and Board Director of Vecata A/S, Mirrx A/S, PledPharma AB, Copenhagen University Proof of Concept financing board, Symbion A/S, Aprea AB and WNT Research AB.
Dr. Jacob Rosenberg, MD, DSc, FRCS, FACS, is professor of surgery at the University of Copnehagen, and head of the surgical department at Herlev Hospital in Copenhagen. He has published more than 500 scientific papers and been invited speaker at numerous congresses and symposia around the world. He was chairman of the board of directors in Dandrit Biotech A/S during 2003-2009 and was here instrumental in the development and initial clinical testing of the Dandrit vaccine.
Dr Tongtis Tongyai, MD is a specialist in Obstetrics and Gynaecology (Post Doctoral Fellow at Quenn Mother Hospital and king's College Hospital, UK and at Johns Hopkins Hospital, USA). After 13 years as an Associate Professor in the Department of Obstetrics and Gynaecology at Ramathibodi Hospital, Dr Tongyai established the blastocyst culture programme of the Blastocyst Center in the Department of Obstetrics and Gynaecology of Praram 9 Hospital in 1998. He is currently the Director of Perfect Women Institute. In addition to bringing to DanDrit medical expertise with a particularly relevant knowledge of cell culture and cell therapy Dr. Tongyai also adds a global business perspective to DanDrit’s board of directors.
Mr. Sune Olsen offers years of experience working with businesses in all aspects of management and operations (Teleworks A/S). Mr. Olsen possesses special competencies within management and strategy in start-up companies. He is one of the major shareholder in DanDrit (Sune Olsen Holding).